Wall Street analysts expect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will post ($1.85) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.95) and the highest is ($1.71). Agios Pharmaceuticals posted earnings per share of ($1.63) in the same quarter last year, which would indicate a negative year over year growth rate of 13.5%. The business is expected to issue its next earnings report on Thursday, November 7th.

On average, analysts expect that Agios Pharmaceuticals will report full year earnings of ($7.12) per share for the current fiscal year, with EPS estimates ranging from ($7.42) to ($6.88). For the next fiscal year, analysts forecast that the company will report earnings of ($7.04) per share, with EPS estimates ranging from ($7.95) to ($6.62). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.17). The company had revenue of $26.22 million for the quarter, compared to analyst estimates of $27.05 million. Agios Pharmaceuticals had a negative net margin of 383.05% and a negative return on equity of 59.89%. Agios Pharmaceuticals’s revenue for the quarter was down 35.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.19) EPS.

Several brokerages recently issued reports on AGIO. Cowen reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Friday, May 31st. BidaskClub lowered Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 6th. Zacks Investment Research raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating and set a $46.00 price target for the company in a research report on Wednesday, August 14th. Royal Bank of Canada set a $89.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, May 23rd. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company’s stock. Agios Pharmaceuticals presently has an average rating of “Hold” and an average price target of $72.50.

Shares of Agios Pharmaceuticals stock traded up $2.32 on Friday, hitting $37.90. The company had a trading volume of 699,998 shares, compared to its average volume of 525,564. Agios Pharmaceuticals has a 1 year low of $33.17 and a 1 year high of $79.17. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.91 and a current ratio of 5.96. The stock has a 50 day moving average of $41.07 and a 200-day moving average of $51.55. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of -6.29 and a beta of 2.22.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wealthstreet Investment Advisors LLC lifted its holdings in Agios Pharmaceuticals by 0.9% during the first quarter. Wealthstreet Investment Advisors LLC now owns 29,415 shares of the biopharmaceutical company’s stock worth $1,984,000 after acquiring an additional 250 shares during the period. California State Teachers Retirement System grew its stake in Agios Pharmaceuticals by 0.4% in the 1st quarter. California State Teachers Retirement System now owns 80,018 shares of the biopharmaceutical company’s stock valued at $5,396,000 after purchasing an additional 334 shares during the period. US Bancorp DE grew its stake in Agios Pharmaceuticals by 82.6% in the 2nd quarter. US Bancorp DE now owns 1,010 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 457 shares during the period. NumerixS Investment Technologies Inc bought a new position in Agios Pharmaceuticals in the 2nd quarter valued at $35,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Agios Pharmaceuticals by 27.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,666 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 779 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Featured Article: Do back-end load funds outperform no-load funds?

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.